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Abstract
Background Cardiovascular risk is increased in patients
with chronic kidney disease (CKD). Fibroblast growth
factor 23 (FGF23) has emerged as an important, indepen-
dent predictor of outcome in CKD patients. High FGF23
may, however, be a reflection of renal tissue resistance to
its actions, reflected by low fractional excretion of phos-
phate (FePi). We evaluated the modifying effect of FePi on
the association between FGF23 and outcome in patients
with CKD stage 3–4.
Methods An analysis was performed in a subset of 166
adult patients of two participating centers of the
MASTERPLAN trial of whom urine samples at baseline
were available to calculate FePi. Outcome was defined as a
composite of death, renal failure (defined as need for renal
replacement therapy or doubling of serum creatinine) and
cardiovascular events (myocardial infarction, cere-
brovascular accident, percutaneous transluminal coronary
angioplasty or coronary artery bypass graft. Patients were
categorized by FGF23 and FePi. A product term was added
to Cox regression and RERIs were calculated.
Results Patients had a median estimated glomerular fil-
tration rate (eGFR) of 36 ml/min/1.73 m2 [interquartile
range (IQR) 27–44], serum phosphate 1.04 mmol/l (IQR
0.92–1.20), FGF23 140 RU/ml (IQR 81–236) and FePi
0.32 (IQR 0.25–0.44). A total of 96 events occurred during
5 years of follow up. LnFGF23 was a significant, inde-
pendent predictor for the composite outcome [hazard ratio
(HR) 2.13, 95 % confidence interval (CI) 1.53–2.95]. FePi
did not modify the relation between FGF23 and outcome in
these patients with CKD.
Conclusions Our study shows that FGF23 itself, but not
its renal tissue resistance as reflected by FePi, is an im-
portant risk factor for clinical events in subjects with CKD
stage 3–4.
Keywords FGF23  Chronic kidney disease 
Cardiovascular risk
Introduction
Chronic kidney disease (CKD) is associated with a high
risk for cardiovascular disease and mortality [1]. This in-
creased risk is attributed to various traditional and non-
traditional risk factors such as hypertension, diabetes [2],
proteinuria [3], uric acid [4] and acidosis [5]. In recent
years the role of disorders in calcium and phosphate
metabolism has been emphasized, with studies reporting
increased cardiovascular risk associations with higher
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serum phosphate [6–12], higher calcium [11], higher
parathormone (PTH) [13], and lower vitamin D levels [14].
Most recently, focus has shifted to fibroblast growth factor
23 (FGF23), a phosphaturic hormone mainly produced by
the osteocyte [15]. FGF23 is associated with cardiovascular
(CV) morbidity and mortality in patients with CKD [16–
18], and is an independent predictor for progression of
kidney failure [16, 17, 19, 20]. Moreover, elevated FGF23
levels have been shown to be a risk factor for CV disease
and mortality in the general population [18, 21, 22].
FGF23 is involved in phosphate metabolism. It inhibits
expression of the sodium-phosphate transporters in the
proximal tubuli of the kidneys, thus promoting renal
phosphate excretion [23]. Elevated FGF23 levels in pa-
tients with CKD may partially be the result of FGF23 re-
sistance. FGF23 resistance can be defined as a state in
which the kidney and the parathyroid glands, the primary
sites of FGF23 action, do not respond optimally to FGF23
by excreting less phosphate and suppressing PTH less ef-
ficiently compared to healthy persons, which drives FGF23
to increase. Classical FGF23 action requires binding to its
receptor, using Klotho as co-factor [24, 25]. It is believed
that tissue Klotho levels of the kidney decline with CKD
and may thus be the mechanism behind FGF23 resistance
[26–31]. Although FGF23 is thought to have effects also
independently from Klotho [32], it is possible that elevated
FGF23 concentrations reflect renal tissue Klotho deficien-
cy, and that FGF23 resistance itself contributes to the in-
creased relative risk regarding outcome. This indeed was
suggested by Dominguez et al. [33] who used fractional
excretion of phosphate (FePi) as a marker of FGF23
resistance, and observed that FePi modified the association
of FGF23 with outcome in 872 patients with relatively mild
CKD [mean estimated glomerular filtration rate
(eGFR)71 ml/min/1.73 m2]. Those considered to be more
FGF23 resistant had worse outcome. We questioned if the
same could be observed in patients with more severe CKD,
a situation associated with increased CV mortality, pro-
gression of CKD and higher FGF23 concentrations.
Patients and methods
Patients
We used baseline data of patients who participated in the
MASTERPLAN (Multifactorial approach and superior
treatment efficacy in renal patients with the aid of nurse
practitioners) study [34]. MASTERPLAN was a rando-
mized controlled clinical trial (ISRCTN73187232) per-
formed in nine Dutch hospitals in which patients with CKD
(eGFR 20–70 ml/min/1.73 m2) were randomized to receive
either usual care by the nephrologist or intensified
treatment with added nurse practitioner support. Inclusion
started in April 2004 and ended in December 2005. In two
centers, baseline 24 h urine was collected and samples
were stored at -80 C. Only patients from these centers
were included in the current analysis as urinary analyses
were required.
Data collection
Details of the study methods are described elsewhere [34].
In brief, baseline measurements included a questionnaire
recording smoking behavior and medication use. Physical
examination consisted of measurement of height, weight
and blood pressure. Laboratory assessment included fasting
serum creatinine, calcium, phosphorus and PTH. Stored
blood samples were used at a more recent date for mea-
suring FGF23 using sandwich enzyme-linked immunosor-
bent assay (ELISA) (Immutopics San Clemente, CA, USA)
measuring the c-terminal FGF23 [35]. The intra- and inter-
assay coefficients of variation of this assay are \5 and
\16 %, respectively [36]. Urine samples were thawed,
acidified, and creatinine, calcium, and phosphate were
measured using standard automated techniques. EGFR was
calculated with the four-point Modification of diet in renal
disease (MDRD) formula [37]. Fractional excretion of
phosphate was calculated as (urine phosphate 9 serum
creatinine)/(serum phosphate 9 urine creatinine). Clinical
outcome in MASTERPLAN has been described elsewhere
[38]. A composite end-point was defined consisting of the
combination of death, CV events (myocardial infarction,
cerebrovascular accident, percutaneous transluminal coro-
nary angioplasty or coronary artery bypass graft) and renal
failure (defined as need for renal replacement therapy,
doubling of serum creatinine or death).
FGF23 resistance
FGF23 increases phosphate excretion through reduced
phosphate re-absorption. Thus, FGF23 resistance can be
considered if a high FGF23 exists together with a low FePi.
Statistical analysis
Baseline characteristics are reported as median values with
interquartile range (IQR) for skewed data and as mean
values with standard deviation (SD) for normally dis-
tributed data. Medians between groups were compared
using the non-parametric independent samples median test.
Natural logarithm transformation was applied for the
skewed data. Spearman correlation coefficients were used
to perform univariate analyses. Survival analyses were
performed using Cox regression analyses in order to adjust
for possible confounding by gender, age, systolic blood
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pressure, eGFR, PTH, proteinuria and smoking. In order to
evaluate if FGF23 resistance expressed as FePi increased
the effect of FGF23 on outcome, patients were categorized
by FGF23 above and below the median combined with
FePi above and below the mean into four categories. A
product term for the categorized FGF23 and FePi was
added again to Cox regression. In the presence of a positive
interaction, the sum of hazard ratios (HR) for the combi-
nation of a high FGF23 and low FePi would be higher than
the theoretical calculated HR of a high FGF23 and high
FePi times the ratio of the HR of a low FGF23 and low
FePi divided by the HR of the reference group. A second
method to calculate the presence and direction of interac-
tion was performed by calculating the relative excess risk
due to interaction (RERI) [39, 40]. The confidence interval
(CI) of the RERI was estimated using jackknife resam-
pling. A positive additive interaction is present if the RERI
is[0 and is statistically significant. Statistical significance
was defined as a two sided p value of\0.05. Statistical
analyses were performed using SPSS 20.0 (IBM SPSS
software, IBM Corp, Armonk, NY, USA) and Stata 11.2
(StataCorp, College Station, TX, USA) software packages.
Results
The two participating centers included 194 patients in the
MASTERPLAN study. Urine samples were available for
166 patients. Baseline characteristics of these 166 patients
grouped by FGF23 and FePi are shown in Table 1. The
median age was 53 (IQR 45, 62) years, most patients were
Caucasian and the median eGFR was 36 (IQR 28, 44) ml/
min/1.73 m2. The median of proteinuria was 0.40 (IQR
0.20, 1.20) g/day, FePi 0.32 (IQR 0.25, 0.44) and FGF23
140 (IQR 81–236) RU/ml. People with higher FGF23
levels more frequently used vitamin D compounds.
Correlations
Univariate analysis between FGF23 and parameters of
kidney function and phosphate metabolism showed a sig-
nificant inverse correlation between FGF23 and eGFR
(R = -0.43, p\ 0.01). We observed a significant positive
correlation between FGF23 and serum phosphate
(R = 0.29, p\ 0.01), FePi (R = 0.36, p\ 0.01), urine
phosphate/creatinine ratio (R = 0.17, p = 0.03) and PTH
(R = 0.30, p\ 0.01). Of note, there was no significant
correlation between FGF23 and serum calcium. In the
multivariate analysis including sex, body mass index
(BMI), age, PTH, eGFR, FePi, serum phosphate, serum
calcium, total cholesterol, systolic blood pressure, protei-
nuria, diabetes and smoking, only eGFR and smoking were
independent predictors of FGF23.
FGF23 resistance
Clinical characteristics of the patients divided by the
combination of FePi and FGF23 are reported in Table 1.
Compared to patients with FGF23 concentrations below
the median, the patients with higher concentrations had
more proteinuria, a higher PTH, a higher phosphate and a
lower eGFR. Patients with high FGF23 were also more
frequently diabetics and more likely to smoke. Patients
with a low FePi had lower serum phosphorus levels, a
lower PTH, total cholesterol and were more likely
female.
Outcome
After a median of 4.8 years of follow up, 96 of the 166
patients (59 %) reached an endpoint defined as death (8/
166), CV event (14/166), renal replacement therapy or
doubling of creatinine (74/166). In the multivariate Cox
regression analysis only lnFGF23, proteinuria and systolic
blood pressure remained independent predictors of the
composite outcome (Table 2). FePi was not associated with
outcome. Moreover, the hazard ratio for LnFGF23 for
outcome did not change after adjustment for FePi
(Table 2). Figure 1 shows the Kaplan–Meier curve for the
composite outcome according to quartiles of FGF23 after
adjustment for baseline covariates.
Tables 3 and 4 further show the hazard ratios for the
associations between FGF23 and FePi categories and out-
come. Cox regression, which was adjusted for age, sex,
smoking, systolic blood pressure, proteinuria, eGFR and
PTH, revealed a hazard ratio for the combination of high
FGF23 and low FePi of 4.15 (95 % CI 1.85–9.30) on the
combined outcome (Table 3). In the absence of hazard
ratio modification, one would have expected the joint effect
of a high FGF23 and low FePi to give a HR of 8.14
[=eln(2.56) ? ln(3.18)]. Likewise, the RERI was -0.60 (95 %
CI -4.81 to 3.70). Similarly, the hazard ratio of a high
FGF23 combined with low FePi on renal outcome was
3.44, lower than expected from the sum of both individual
factors, HR = 7.77 [=eln(2.40) ? ln(3.22)].
Discussion
In this study we tested the hypothesis that FGF23 resis-
tance may contribute to the increased risk for morbidity
and mortality associated with elevated FGF23 levels in
patients with advanced CKD. This hypothesis was based on
a recent study showing interaction between FePi and
FGF23 levels on outcome in patients with mild CKD [33].
Our study showed that there was no interaction between
FGF23 levels and FePi on this outcome, and thus we could
J Nephrol (2015) 28:477–484 479
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not confirm this hypothesis in subjects with more advanced
CKD and higher FGF23. This suggests that in patients with
advanced CKD, FGF23 itself and not FGF23 resistance
determines the risk for adverse outcome.
This study confirmed that FGF23 is an independent
predictor of outcome. Moreover, multivariable adjustments
that included FePi did not mitigate the HR of FGF23.
FGF23 concentrations increase during progression of CKD
Table 1 Baseline characteristics of patients grouped by FGF23 and FePi (n = 166)
Variable Total group
(n = 166)
Low FGF23, high
FePi (n = 31)
Low FGF23, low
FePi (n = 52)
High FGF23, high
FePi (n = 51)
High FGF23, low
FePi (n = 32)
p value
Gender, male, n (%) 112 (67) 26 (84) 28 (54) 40 (78) 18 (56) 0.01
Age, years (range) 53 (45–62) 52 (43–64) 53 (45–61) 54 (50–63) 49 (43–64) 0.38
BMI (kg/m2) 26 (24–29) 26 (23–27) 26 (23–28) 27 (24–30) 26 (23–31) 0.47
Race (Caucasian) 160 30 48 51 31 0.22
Cause of CKD
Diabetic 14 1 4 7 2 0.62
Renovascular 9 1 3 4 1
Glomerulonephritis 41 7 18 10 6
Interstitial 29 8 6 8 7
Congenital 8 3 3 0 2
Cystic kidney disease 22 3 7 8 4
Unknown 33 6 9 9 9
Other 10 2 2 5 1
Systolic BP (mmHg) 126 (118–139) 124 (116–134) 124 (116–135) 130 (119–144) 125 (118–136) 0.44
Diastolic BP (mmHg) 75 (70–81) 75 (71–78) 76 (70–81) 75 (70–83) 76 (68–83) 0.81
eGFR (MDRD4, ml/
min/1.73 m2)
36 (27–44) 36 (29–45) 41 (36–52) 27 (20–34) 36 (27–42) \0.01
Proteinuria (g/24 h) 0.40 (0.20–1.20) 0.40 (0.20–1.20) 0.30 (0.10-0.58) 0.80 (0.30–1.50) 0.60 (0.20–1.38) 0.01
Total cholesterol
(mmol/l)
4.99 ± 0.98 5.10 (4.50–5.80) 5.00 (4.40–5.50) 4.80 (4.00–5.30) 5.15 (4.53–6.08) 0.18
Serum phosphate
(mmol/l)
1.04 (0.92-1.20) 1.02 (0.94–1.13) 1.00 (0.89–1.09) 1.17 (0.96–1.40) 1.04 (0.90–1.20) 0.03
Serum calcium
(mmol/l)
2.35 ± 0.15 2.37 (2.30–2.50) 2.38 (2.28–2.44) 2.34 (2.26–2.42) 2.33 (2.22–2.40) 0.49
Serum albumin
(mmol/l)
40 ± 4 41 (40–43) 40 (38–42) 39 (37–42) 40 (37–41) 0.10
Serum PTH (pmol/l) 10.15
(6.68–16.18)
10.15
(8.18–16.73)
9.00 (4.65–12.00) 14.25
(9.00–23.23)
10.00
(6.08–15.85)
\0.01
Serum cFGF-23 (RU/ml) 140 (81–236) 78 (54–114) 81.25
(54.10–115.00)
278 (203–439) 204 (159–289) \0.01
Fractional phosphate
excretion
0.32 (0.25–0.44) 0.41 (0.36–0.46) 0.24 (0.19–0.28) 0.49 (0.40–0.54) 0.26 (0.22–0.29) \0.01
Fractional calcium
excretion
0.00 (0.00–0.01) 0.00 (0.00–0.01) 0.00 (0.00–0.01) 0.00 (0.00–0.01) 0.00 (0.00–0.01) 0.99
Vitamin D drugs (n, %) 33 (20) 3 (10) 5 (10) 18 (35) 7 (22) 0.004
Diabetes 35 2 8 18 7 0.01
Smokers 27 2 6 15 4 0.02
Events/PY 96/792 11/158 25/257 37/236 23/141
Events/1000 PY 121 70 97 157 163
Median with interquartile ranges (25–75 %) for skewed data
Mean with standard deviation (±SD) for normally distributed data
FGF23 fibroblast growth factor 23, FePi fractional excretion of phosphate, BMI body mass index, CKD chronic kidney disease, BP blood
pressure, eGFR estimated glomerular filtration rate, MDRD4 4-point modification of diet in renal disease, PTH parathormone, PY person years
480 J Nephrol (2015) 28:477–484
123
and several studies have shown that FGF23 is associated
with mortality in hemodialysis patients as well in patients
with CKD [16, 17, 41–43]. Also in our analysis FGF23
remained a predictor of outcome after adjustment of eGFR.
Interestingly, the HR of eGFR itself on the composite
outcome that included progression of CKD was lost in the
multivariable model. This suggests that the well-estab-
lished risk of CKD may actually be accounted for by high
levels of FGF23 that accompany CKD. Obviously,
increased FGF23 levels might merely reflect the severity of
other unmeasured risk factors. Cohort studies, for instance,
have reported associations of FGF23 with left ventricular
hypertrophy [44, 45], progression of kidney failure [16, 19,
20], and with several cardiovascular risk factors, such as
endothelial dysfunction and arterial stiffness, in the general
population as well as in early CKD, in the absence of
clinically evident disturbances in phosphate metabolism
[21, 46, 47].
Our findings appear to contrast with the report by
Dominguez et al. [33] who concluded that the association
of FGF23 with outcome was reinforced if high FGF23 was
Table 2 Univariate and
multivariate Cox regression
analysis for combined outcome
HR hazard ratio, CI confidence
interval, for other abbreviations,
see Table 1
Univariate Multivariate
HR CI p value HR CI p value
LN FGF23 2.17 1.65–2.84 \0.01 2.13 1.54–2.95 \0.001
FePi 3.39 0.86–13.47 0.082 0.23 0.04–1.52 0.13
Serum phosphate 3.57 1.72–7.45 \0.001 2.13 0.87–5.19 0.10
Proteinuria 1.27 1.15–1.41 \0.001 1.25 1.11–1.41 \0.001
MDRD 0.97 0.96–0.99 0.005 0.99 0.97–1.02 0.59
Age 0.99 0.97–1.00 0.158 0.99 0.97–1.00 0.11
Gender (male) 1.32 0.85–2.09 0.215 0.67 0.40–1.11 0.12
Smoking 1.75 1.08–2.84 0.022 0.98 0.54–1.75 0.93
Systolic blood pressure 1.02 1.00–1.04 0.001 1.02 1.00–1.03 0.02
PTH 1.02 1.00–1.03 0.017 1.00 0.98–1.02 0.98
Fig. 1 Cox curve for quartiles of FGF23 and the effect on composite
outcome. Adjusted for age, sex, smoking, systolic blood pressure,
proteinuria, eGFR, TmP/GFR, serum phosphate and PTH. FGF23,
fibroblast growth factor 23; eGFR, estimated glomerular filtration
rate; TmP/GFR, ratio of the maximum rate of tubular phosphate
reabsorption to the glomerular filtration rate; PTH, parathormone
Table 3 Multivariate cox regression on combined outcome for
categories defined by FGF23 below and above the median combined
with FePi below and above the mean
Combined survival Participants Events HR 95 % CI
Low FGF23/high FePi 31 11 1 Reference
Low FGF23/low FePi 52 25 2.56 1.13–5.80
High FGF23/high FePi 51 37 3.18 1.47–6.87
High FGF23/low FePi 32 23 4.15 1.85–9.30
This model included FGF23 and FePi as categorical variables and
their product term
The model was adjusted for factors shown and age, sex, smoking,
systolic blood pressure, proteinuria, eGFR, PTH
Hazard ratio product for the product term is 0.51 (95 % CI
0.19–1.34), p = 0.17
RERI is -0.60 (95 % CI -4.81 to 3.70), p = 0.79
RERI, relative excess risk due to interaction, for other abbreviations,
see previous tables
Table 4 Multivariate cox regression on renal outcome for categories
defined by FGF23 below and above the median combined with FePi
below and above the mean
Renal survival Participants Events HR 95 % CI
Low FGF23/high FePi 31 9 1 Reference
Low FGF23/low FePi 52 20 2.40 0.81–6.34
High FGF23/high FePi 51 34 3.22 1.31–7.84
High FGF23/low FePi 32 18 3.44 1.37–8.62
This model included FGF23 and FePi as categorical variables and
their product term
The model was adjusted for factors shown and age, sex, smoking,
systolic blood pressure, proteinuria, eGFR, and PTH
Hazard ratio product for the product term is 0.44 (95 % CI 0.14–1.41)
RERI is -1.18 (95 % CI -8.10 to 5.73), p = 0.74
For all abbreviations, see previous tables
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accompanied by a low FePi, suggesting that kidney FGF23
resistance modifies the association between FGF23 and
outcome. There are several possible explanations for this
discrepancy. The most important factor is the obvious
difference in patient population and outcome. Dominguez
et al. studied patients that participated in the Heart and Soul
study, which included patients with prevalent occlusive
coronary artery disease and normal to slightly decreased
eGFR, mainly attributed to vascular disease. Importantly,
in the eGFR range of the Heart and Soul study (stage II
CKD), CKD is not an important contributor to overall risk
[1]. In contrast, our patients had moderate-severe CKD and
often defined kidney disease whereby outcome was mainly
determined by renal failure. The second explanation could
be the difference in methodology. We performed interac-
tion analyses by calculating the direction of the interaction
using the low FGF23 and high FePi as reference group.
Dominguez documented the p-value though the direction
seems opposite and used low FGF23 and low FePi as
reference group.
Another study examined the association of a poor
phosphaturic response to FGF23, as a sign of FGF23
resistance, with abdominal aortic calcification in CKD
stages 3–4 [48]. In this study, FGF23 correlated well to
FePi except in the group of patients with severe aortic
calcification, while eGFR and PTH correlated well to FePi
irrespective of the amount of calcification, suggesting an
association between FGF23 resistance and severe aortic
calcification. A shortcoming of this study however is that
the ratio of FePi to FGF23 (FePi/FGF23) was used as a
marker of resistance where this ratio was mostly deter-
mined by the denominator FGF23 as there was no differ-
ence in FePi between groups. Therefore, outcome on
calcification score was mainly determined by FGF23.
Overall, we cannot exclude the possibility that FePi values
might indeed modify FGF23-related risk in patients with
early-stage CKD. In patients with more severe CKD,
however, the increased risk is predominantly determined
by the higher FGF23 levels, and not by kidney resistance of
its effects. Furthermore, FePi was not associated with
outcome at either univariate or multivariate analysis. Pre-
vious studies showed that also FePi was not associated with
mortality and cardiovascular events in a model adjusted for
FGF23 and eGFR [17, 33, 49]. This might be because in
CKD other (non-defined) risk factors might outweigh the
risk of tubular resistance to FGF23, or that more advanced
tubular damage inhibits phosphate reabsorption by other
mechanisms than the physiological effects of FGF23, as
can be observed, for instance, in Fanconi’s syndrome.
Our results thus refute a significant contribution of
FGF23-resistance to outcome in patients with CKD 3-4. In
addition to the arguments described above, it should,
however, be borne in mind that there lacks a good
representative parameter and validated measure of FGF23-
resistance, in that both TmP/GFR (ratio of the maximum
rate of tubular phosphate reabsorption to the glomerular
filtration rate) and FePi might not reflect FGF23-resistance
optimally, especially in the setting of more advanced CKD.
Our study has some limitations, all being consequences
of the post hoc nature of the current analysis. The main
limitation is the relatively small number of patients inclu-
ded. Although the event rate was high, the events were
mainly in the group of patients with highest FGF23 levels.
Especially for the interaction analysis that we performed, a
larger number of patients would have been preferable. Due
to the small number of patients, we used a composite end-
point. Our study had a low power to evaluate single end-
points with adjustment for competing risks. Another lim-
itation is that the study is a post hoc analysis of mostly
Caucasian patients with more severe CKD and results
might not be directly applicable to other populations.
Furthermore, although serum phosphate was measured in a
fasting state, FePi was not a timed specimen before blood
sample collection but was calculated from 24 h urine
samples. This might have led to higher FePi values, and an
underestimation of FGF23 resistance because fasting
phosphate concentrations are generally lower than the
average daytime value. A final limitation is that we used a
composite end-point, and that in larger studies outcomes
may differ for individual components of the currently used
composite end-points.
Strengths of our data are the prospectively collected
data, and the inclusion primarily of patients in a stage of
CKD where CKD has proven impact on clinical outcome.
Conclusion
In conclusion, in this study in patients with a median eGFR
of 36 (IQR 27–44) ml/min/1.73 m2, FePi did not modify
the association of FGF23 with outcome. Therefore, in
advanced CKD, the role of FGF23 resistance expressed by
FePi is negligible compared to the risk predicted by
increased concentrations of FGF23 itself.
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